Precision Medicine

With a major cash infusion, CND Life Sciences is set to scale its skin-based test for Parkinson's, signaling a shift from subjective diagnosis to objective data.

An award for a Virginia nurse is more than a headline. It's a signal of a strategic revolution in healthcare, where community clinics become global powerhouses.

By partnering with major CROs, Revolune is tackling a key bottleneck in advanced tissue analysis. This new ecosystem could change how labs of all sizes innovate.

Strong Q2 results, pivotal deals with AstraZeneca and MSK, and a clear path to profitability signal SOPHiA GENETICS is converting its AI platform into market leadership.

A strategic delegation of 15 AI startups signals a new era. Taipei is not just selling tech; it's building a deep innovation ecosystem with Japan.

A new strategic alliance aims to dismantle geographic barriers in oncology by decentralizing diagnostics, a move with profound implications for patient access.

IDEAYA Biosciences advances its breakthrough melanoma drug toward FDA review while its $1.24B cash runway fuels a deep pipeline targeting cancer's toughest codes.

MGI Tech's strategic alliance with NCSTAR in Queensland is set to accelerate medical breakthroughs by providing a full suite of cutting-edge 'multi-omics' tools.

LabPMM's new global KMT2A MRD test offers ultra-sensitive monitoring for aggressive leukemias, aiming to improve patient outcomes and streamline trials for menin inhibitors.

As ProMIS Neurosciences preps its Q2 update, all eyes are on its lead Alzheimer's drug. Can its "sniper-like" precision deliver efficacy without the side effects plaguing the field?

Gene Solutions’ academy in Malaysia signals a shift from complex genomic data to empowering clinicians with actionable insights for a new era of cancer care.

BWXT divests its medical arm to Nordic Capital, refocusing on its nuclear core while the private equity giant doubles down on the booming radiopharma market.

Human Longevity's new low-cost whole genome sequencing promises predictive health for all, but its true power lies in its AI and a vast new data asset.

A pivotal CMS ruling grants Carlsmed's AI-driven spinal implants a dedicated payment code, unlocking market access and signaling a new era for med-tech.

With $100M in total funding, bioinformatics firm Inocras plans to challenge U.S. precision oncology leaders by leveraging its whole-genome sequencing success in Asia.

Curium's landmark $8 billion acquisition of Lantheus is set to create a global powerhouse in nuclear medicine, reshaping patient care and the competitive landscape.

Dr. Howard Bailey, a top cancer center leader, joins Cofactor Genomics. It's a strategic bet on RNA's power to finally predict immunotherapy success.

A landmark study validates Astrin Biosciences' proteomic test, Certitude, boasting >92% accuracy and offering new hope for women with dense breasts.

AB2 Bio's partnership with Nippon Shinyaku for Tadekinig alfa signals a new era for ultra-rare pediatric care and highlights a savvy biotech financing strategy.